Yuhui Huang
Immunology · 2012–2013
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Immunology — 19 citations into it; #1,784 of 2,160 by trust here, #1,551 by citations
- Oncology — 17 citations into it
Whom Yuhui Huang trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Yuhui Huang overall
Papers from Yuhui Huang's perspective
Ordered by how strongly the researchers Yuhui Huang trusts endorse each paper. Same corpus, a different order for every researcher.
- Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. (Cancer Research)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy (Science)
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
- HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. (Cancer Cell)
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells (Nature)
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm (Nature Immunology)
- Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. (Journal of Clinical Oncology)
- Molecular mechanisms and clinical applications of angiogenesis (Nature)
- VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. (Cancer Research)